Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16368808 | 0.92 | CYP4F2 (0.43) | CYP4F2CYP4A11ALDH1A1TSHRTP53 | |
| SCHEMBL16368797 | 0.92 | CYP4F2 (0.47) | CYP4F2CYP4A11ALDH1A1TSHRTP53 | |
| SCHEMBL6258085 | 0.85 | DGAT1 (0.37) | CYP4F2CYP4A11DGAT1 | |
| SCHEMBL17085275 | 0.84 | CYP4F2 (0.38) | CYP4F2CYP4A11ALDH1A1TSHRTP53 | |
| SCHEMBL2022397 | 0.82 | DGAT1 (0.44) | CYP4F2CYP4A11ALDH1A1TSHRDGAT1 | |
| SCHEMBL19906350 | 0.79 | CYP4F2 (0.39) | CYP4F2CYP4A11ALDH1A1TSHRTP53 | |
| SCHEMBL16368829 | 0.79 | DGAT1 (0.50) | CYP4F2CYP4A11ALDH1A1TSHRTP53 | |
| SCHEMBL13875095 | 0.79 | ABCB11 (0.32) | CYP4F2CYP4A11 | |
| SCHEMBL19009193 | 0.78 | CYP4F2 (0.41) | CYP4F2CYP4A11TSHRDGAT1 | |
| SCHEMBL4570355 | 0.78 | CYP4F2 (0.44) | CYP4F2CYP4A11DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170112939-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | Ascendis Pharma Ophthamology Division A/S (DK) | 2017-04-27 | — | — | US | disclosed |
| US-20150010634-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | Ascendis Pharma Ophthamology Division A/S (DK) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112939-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | PDE6C, ALDH1A2, UACA | CYP4F2 2815/4885CYP4A11 1132/4885ALDH1A1 239/4885 |
| US-20150010634-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | PDE6C, ALDH1A2, UACA | CYP4F2 2815/4885CYP4A11 1132/4885ALDH1A1 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.